- GE Discovery IQ PET/CT provides advanced early disease detection capabilities for Egyptian
- Nile Scan aims to conduct a PET/CT exam to over 3,000 patients a year
- Nile Scan installed GE’s first digital mammography system in Egypt in 2000
As part of its ongoing commitment to provide quality healthcare for Egyptians and accelerating solutions to detect cancer early, GE Healthcare today announced that it has supplied Nile Scan & Labs with its exceptional Positron Emission Tomography/ Computed Tomography (PET/C
business unit
tags
- GE Discovery IQ PET/CT provides advanced early disease detection capabilities for Egyptian
- Nile Scan aims to conduct a PET/CT exam to over 3,000 patients a year
- Nile Scan installed GE’s first digital mammography system in Egypt in 2000
As part of its ongoing commitment to provide quality healthcare for Egyptians and accelerating solutions to detect cancer early, GE Healthcare today announced that it has supplied Nile Scan & Labs with its exceptional Positron Emission Tomography/ Computed Tomography (PET/C
business unit
tags
- Une plateforme avancée d'imagerie mammaire, Senographe Pristina; prévoit de refaçonner l'expérience de mammographie pour offrir plus de confort, de confiance et de clarté à toutes les patientes, les technologues et les radiologistes
- Conçue pour aider à réduire la douleur, l'inconfort et l'anxiété des patientes
TORONTO, le 23 mars 2017 /CNW/ - GE Santé est ravie de lancer la nouvelle plateforme, Senographe Pristinatm, dans le cadre de notre engagement à combattre le cancer du sein en encourageant la détection précoce.
business unit
- Advanced breast imaging platform, Senographe Pristina; expected to reshape the mammography experience with comfort, confidence and clarity for Patients, Technologists and Radiologists
- Purposefully Designed to help reduce pain, discomfort and anxiety for patients
TORONTO, March 23, 2017 /CNW/ - GE Healthcare is delighted to launch the new Senographe Pristina™, in our commitment to fighting breast cancer by
business unit
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended the suspension of the European marketing authorizations for four linear gadolinium contrast agents (GdCAs) because of the presence of small amounts of gadolinium in the brain. No harm linked to gadolinium in the brain has been reported.
business unit
Tiedote 14.3.2017 - GE Healthcare lahjoittaa Aalto-yliopistolle neljä CARESCAPE B650 -potilasvalvontamonitoria. Lahjoituksen tarkoitus on antaa bioinformaatioteknologian opiskelijoille käytännön kokemusta sairaaloissa käytössä olevista terveysteknologian laitteista.
Monitorit luovutetaan Aalto-yliopiston Terveysteknologiatalon avajaisten yhteydessä Otaniemessä tänään 14.3.2017 klo 17.
Monitorien käyttö opetuksessa hyödyttää opiskelijoita, mutta siitä on etua myös alan osaajia runsaasti työllistävälle GE Healthcarelle.